A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

June 1, 2028

Study Completion Date

June 1, 2028

Conditions
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

DRUG

Letermovir

Given PO or IV

Trial Locations (19)

19104

Children's Hospital of Philadelphia, Philadelphia

19803

Alfred I duPont Hospital for Children, Wilmington

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

23298

VCU Massey Comprehensive Cancer Center, Richmond

32207

Nemours Children's Clinic-Jacksonville, Jacksonville

35233

Children's Hospital of Alabama, Birmingham

37203

The Children's Hospital at TriStar Centennial, Nashville

38105

Saint Jude Children's Research Hospital, Memphis

48201

Children's Hospital of Michigan, Detroit

49503

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

70118

Children's Hospital New Orleans, New Orleans

75230

Medical City Dallas Hospital, Dallas

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

78229

Methodist Children's Hospital of South Texas, San Antonio

94158

UCSF Medical Center-Mission Bay, San Francisco

94609

UCSF Benioff Children's Hospital Oakland, Oakland

All Listed Sponsors
lead

Children's Oncology Group

NETWORK

NCT05711667 - A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients | Biotech Hunter | Biotech Hunter